Bleomycin-induced pulmonary fibrosis is attenuated by an antibody against KL-6. (1st August 2013)
- Record Type:
- Journal Article
- Title:
- Bleomycin-induced pulmonary fibrosis is attenuated by an antibody against KL-6. (1st August 2013)
- Main Title:
- Bleomycin-induced pulmonary fibrosis is attenuated by an antibody against KL-6
- Authors:
- Xu, Ling
Yang, Danrong
Zhu, Songlei
Gu, Jie
Ding, Fengming
Bian, Wei
Rong, Zhaohui
Shen, Ce - Abstract:
- ABSTRACT: Background : Elevated levels of KL-6 are reported in the serum and/or bronchoalveolar lavage fluid (BALF) of patients with interstitial lung disease (ILD) and are useful to estimate the severity and prognosis of the disease. However, whether the anti-KL-6 antibody could attenuate pulmonary fibrosis remains unclear. Objectives : This study aims to investigate the therapeutic effects and mechanisms of anti-KL-6 antibody on bleomycin-induced pulmonary fibrosis. Methods : A mouse model of pulmonary fibrosis was established by intratracheal injection of bleomycin (5 mg/kg). Mouse received anti-KL-6 antibody (20 ug/day, once a day) from day 7 to 21 after bleomycin injection. The effects of anti-KL-6 antibody were evaluated by pathological examination, measuring hydroxyproline measurements in lung tissues, leukocyte counts in BALF and the expression of collagen type I and type III using qRT-PCR. The expression of profibrotic cytokine (transforming growth factor-β1, TGF-β1 ), antifibrotic cytokine (hepatocyte growth factor, HGF), and KL-6 in lung tissues were analyzed by ELISA. The apoptosis of epithelial cell was examined by TUNEL staining. Results : Anti-KL-6 antibody significantly reduced the number of alveolar inflammatory leukocytes (total and differential counts) in BALF of mice with bleomycin-induced pulmonary fibrosis as well as the content of hydroxyproline in the lung tissues. Treatment with anti-KL-6 antibody downregulated the expression of collagen type I,ABSTRACT: Background : Elevated levels of KL-6 are reported in the serum and/or bronchoalveolar lavage fluid (BALF) of patients with interstitial lung disease (ILD) and are useful to estimate the severity and prognosis of the disease. However, whether the anti-KL-6 antibody could attenuate pulmonary fibrosis remains unclear. Objectives : This study aims to investigate the therapeutic effects and mechanisms of anti-KL-6 antibody on bleomycin-induced pulmonary fibrosis. Methods : A mouse model of pulmonary fibrosis was established by intratracheal injection of bleomycin (5 mg/kg). Mouse received anti-KL-6 antibody (20 ug/day, once a day) from day 7 to 21 after bleomycin injection. The effects of anti-KL-6 antibody were evaluated by pathological examination, measuring hydroxyproline measurements in lung tissues, leukocyte counts in BALF and the expression of collagen type I and type III using qRT-PCR. The expression of profibrotic cytokine (transforming growth factor-β1, TGF-β1 ), antifibrotic cytokine (hepatocyte growth factor, HGF), and KL-6 in lung tissues were analyzed by ELISA. The apoptosis of epithelial cell was examined by TUNEL staining. Results : Anti-KL-6 antibody significantly reduced the number of alveolar inflammatory leukocytes (total and differential counts) in BALF of mice with bleomycin-induced pulmonary fibrosis as well as the content of hydroxyproline in the lung tissues. Treatment with anti-KL-6 antibody downregulated the expression of collagen type I, TGF-β1 and KL-6, upregulated the expression of HGF and inhibited the apoptosis of epithelial cells. Conclusions : These findings indicated the anti-KL-6 antibody may potentially be developed as a useful inhibitor of pulmonary fibrosis. … (more)
- Is Part Of:
- Experimental lung research. Volume 39:Number 6(2013:Jun.)
- Journal:
- Experimental lung research
- Issue:
- Volume 39:Number 6(2013:Jun.)
- Issue Display:
- Volume 39, Issue 6 (2013)
- Year:
- 2013
- Volume:
- 39
- Issue:
- 6
- Issue Sort Value:
- 2013-0039-0006-0000
- Page Start:
- 241
- Page End:
- 248
- Publication Date:
- 2013-08-01
- Subjects:
- hepatocyte growth factor -- interstitial lung disease -- KL-6 -- pulmonary fibrosis -- transforming growth factor-β1
Lungs -- Periodicals
Lungs -- Diseases -- Periodicals
Lung Diseases
Lung -- physiology
Respiratory System
616.24 - Journal URLs:
- http://informahealthcare.com/loi/elu ↗
http://www.tandfonline.com/loi/ielu20 ↗
http://informahealthcare.com ↗ - DOI:
- 10.3109/01902148.2013.798056 ↗
- Languages:
- English
- ISSNs:
- 0190-2148
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3839.440000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 205.xml